Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

ORTX Orchard Therapeutics

Watchlist
0.4460.0000.00%
Close 11/25 13:00 ET
0.460
+0.014+3.09%
Post Mkt Price 11/25 16:48 ET
High
0.460
Open
0.460
Turnover
8.17K
Low
0.446
Pre Close
0.446
Volume
17.97K
Market Cap
56.53M
P/E(TTM)
Loss
52wk High
1.550
Shares
126.69M
P/E(Static)
Loss
52wk Low
0.412
Float Cap
34.47M
Bid/Ask %
-11.11%
Historical High
21.640
Shs Float
77.24M
Volume Ratio
0.17
Historical Low
0.412
Dividend TTM
--
Div Yield TTM
--
P/B
0.46
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.02%
Amplitude
3.09%
Avg Price
0.454
Lot Size
1
Float Cap
34.47M
Bid/Ask %
-11.11%
Historical High
21.640
Shs Float
77.24M
Volume Ratio
0.17
Historical Low
0.412
Dividend TTM
--
P/B
0.46
Dividend LFY
--
Turnover Ratio
0.02%
Amplitude
3.09%
Avg Price
0.454
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Orchard Therapeutics Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing and commercializing gene therapies for patients with rare disorders. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). The company was founded by Nicolas Koebel and Andrea Spezzi in August 2018 and is headquartered in London, the United Kingdom.
CEO: Dr. Hubert Gaspar
Market: NASDAQ
Listing Date: 10/31/2018
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist